Kinase targeting in basal-like breast cancer: STK32C.
Fuente:
Zenodo
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Recurso digital |
| Veröffentlicht: |
Zenodo
2025
|
| Online-Zugang: | |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| _version_ | 1866902264511201280 |
|---|---|
| author | Mamoor, Shahan |
| author_facet | Mamoor, Shahan |
| contents | <p dir="ltr">Breast cancer can be distinguished into two broad groups, luminal and basal, based on cytologic, morphologic, cytoskeletal and differentiation-based features. While luminal breast cancers can be positive for expression of a hormone receptor (ESR/PGR/AR) or a growth factor receptor (ERBB2) and targeted accordingly clinically, basal-like breast cancers cannot. Inadequate long-term control of disease (e.g., partial response [PR] or recurrence/relapse) reflects limited effectiveness of existing drugs that treat basal subtype disease. Here we utilized whole transcriptome technologies (5, 6) to define the basal-like breast cancer kinome and phosphatome by measuring total transcription in the primary tumors of humans with basal-like as compared to luminal A and luminal B breast cancer to identify basal-like signaling features. We describe one member of a group of kinases up-regulated and differentially expressed in human basal-like breast cancer, STK32C, as a catalytically available enzyme and candidate therapeutic target for the adjunctive medical treatment of basal subtype breast cancer. </p> |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_16928984 |
| institution | Zenodo |
| language | |
| publishDate | 2025 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | Kinase targeting in basal-like breast cancer: STK32C. Mamoor, Shahan <p dir="ltr">Breast cancer can be distinguished into two broad groups, luminal and basal, based on cytologic, morphologic, cytoskeletal and differentiation-based features. While luminal breast cancers can be positive for expression of a hormone receptor (ESR/PGR/AR) or a growth factor receptor (ERBB2) and targeted accordingly clinically, basal-like breast cancers cannot. Inadequate long-term control of disease (e.g., partial response [PR] or recurrence/relapse) reflects limited effectiveness of existing drugs that treat basal subtype disease. Here we utilized whole transcriptome technologies (5, 6) to define the basal-like breast cancer kinome and phosphatome by measuring total transcription in the primary tumors of humans with basal-like as compared to luminal A and luminal B breast cancer to identify basal-like signaling features. We describe one member of a group of kinases up-regulated and differentially expressed in human basal-like breast cancer, STK32C, as a catalytically available enzyme and candidate therapeutic target for the adjunctive medical treatment of basal subtype breast cancer. </p> |
| title | Kinase targeting in basal-like breast cancer: STK32C. |
| url | https://doi.org/10.5281/zenodo.16928984 |